Meiji

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

Japanese regulator clears the drug for first-line use in NSCLC. AstraZeneca’s blockbuster-in-waiting lung cancer treatment Tagrisso has just been approved in Japan as a first-line treatment ... Dave Fredrickson, Executive Vice President, Head of the

Envision Pharma Group relocates to support growth

The agency now has 14 offices, five of which are based in the UK, six are in the US, and a further three in Serbia, Australia and Japan.

Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Astellas acquires UK gene therapy company Quethera. Japan’s Astellas Pharma is to acquire UK-based gene therapy company Quethera for $85m. ... The drug is already approved in other major markets, including Europe, Japan, Australia and Canada.

FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo

Kyowa Kirin has been selling Poteligeo in Japan since 2012, and the company says its approval in the US is a key milestone on the path to becoming a  global specialty ... Sales of Poteligeo in Japan were 1.9bn yen ($17m) in fiscal 2017, and are

New cancer drugs can’t quite plug the revenue hole at AZ

Overall sales fell 5% to $10.33bn, however, thanks to generic competition taking another chunk out of cholesterol drug Crestor (rosuvastatin) sales, particularly in Europe and Japan. ... its launch in Japan, while Tagrisso grew 82% to $760m on the back

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]